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and opportunities1087-2418 Copyright  2018 The Aa a a,bHannah C. Copley , Madhivanan Elango , and Vasilis KosmoliaptsisPurpose of review
Donor–recipient human leukocyte antigen (HLA) matching improves outcomes after solid-organ
transplantation, but current assessment of HLA incompatibility is inadequate as it does not consider the
relative immunogenicity of individual HLA mismatches. In this article, we review existing strategies for
assessing HLA immunogenicity and discuss current challenges and future opportunities in this field.
Recent findings
Current HLA immunogenicity algorithms focus primarily on the humoral component of the alloimmune
response and aim to determine a measure of ‘dissimilarity’ between donor and recipient HLA. This can be
achieved by deriving information from comparison of donor and recipient HLA at the amino acid
sequence, structural and/or the physicochemical level, accounting for both B-cell and T-cell pathways of
alloreactivity. Substantial evidence now supports the superiority of this molecular definition of HLA
incompatibility, over conventional enumeration of HLA antigenic differences, for assessing the risk of
humoral alloimmunity and for predicting graft outcomes after transplantation.
Summary
Significant progress has been made in developing computational HLA immunogenicity algorithms that offer
exciting opportunities for a more rational approach to determining the degree of donor–recipient HLA
incompatibility and to defining HLA-related immunological risk. A number of challenges now need to be
overcome to enable their implementation into clinical practice.
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properly cited.Donor and recipient human leukocyte antigen
(HLA) incompatibility is the main immunological
barrier to successful organ transplantation. HLA
matching has a beneficial effect on solid organ
transplant outcomes, including on graft function
and on graft and patient survival, although the
magnitude of this effect varies in different organs
[1]. Due to the extensive polymorphism of the HLA
system and the limited size of the donor organ pool,
HLA matching is difficult to achieve and most recip-
ients receive HLA mismatched grafts. Moreover,
the benefits of minimizing the number of donor–
recipient HLA incompatibilities must be balanced
against the, often competing, interests of ensuring
equity of access to transplantation and of reducing
the detrimental effects of prolonging the length of
time on the transplant waiting list. Consequently,
even though HLA matching is incorporated into
many deceased-donor organ allocation schemes,uthor(s). Published by Wolters Kluwebility has progressively diminished in favor of
increasing reliance on immunosuppression therapiesr Health, Inc. www.co-transplantation.com
KEY POINTS
 Computational HLA immunogenicity algorithms offer
exciting opportunities for improved assessment of HLA
incompatibility and of the associated immunological
risk, compared with conventional HLA mismatch grade.
 Current HLA immunogenicity algorithms derive
information from comparison of donor and recipient
HLA at the amino acid sequence, structural and/or the
physicochemical level, accounting for both B-cell and
T-cell pathways of alloreactivity, to predict the risk of
humoral alloimmune responses after transplantation.
 Despite significant progress, a number of challenges
need to be overcome, most notably algorithm
refinement and consensus in research methodology,
to enable implementation of molecular HLA mismatch
methods into clinical practice.
Histocompatibilityto improve graft outcomes. It is evident, however,
that HLA incompatible allografts necessitate the use
of heavier immunosuppression, a major cause of
recipient morbidity and mortality, and increase the
risk of sensitization which can severely limit the
opportunity for repeat organ transplantation.
The principles of HLA matching for organ allo-
cation and of evaluating the immunological risk
associated with a particular donor–recipient HLA
combination have remained largely unchanged for
many decades. Histocompatibility assessment, cur-
rently focuses almost entirely on HLA-A, HLA-B and
HLA-DR loci, is based on counting HLA antigenic
differences at the serological level and is predicated
on the assumption that all mismatches within an
HLA locus are of equal significance to transplant
outcomes. However, it is now increasingly being
recognized that the conventional approach to
assessment of HLA compatibility is inadequate. Cen-
tral to this notion is the realization that the capacity
of a donor HLA to induce immune responses is not
an intrinsic property of the mismatched alloantigen
but that it is critically dependent on the HLA phe-
notype of the recipient. Recent advances in molec-
ular sequence technology, increasing availability of
high quality, crystallographically resolved, HLA
structures and computational approaches to study-
ing B-cell and T-cell epitopes offer exciting oppor-
tunities for a more rational approach to determining
HLA compatibility and to defining HLA-related
immunological risk. In this article, we review exist-
ing strategies for assessing HLA immunogenicity,
including amino acid sequence, structural and phys-
icochemical approaches, focusing on both B-cell
and T-cell pathways of alloreactivity. We also dis-
cuss current challenges and opportunities in the478 www.co-transplantation.comfield and consider future research directions that
might transform clinical practice to maximize the
benefits of transplantation.ASSESSMENT OF HUMAN LEUKOCYTE
ANTIGEN IMMUNOGENICITY AT THE
AMINO ACID SEQUENCE LEVEL
The immunogenicity of nonself-antigenic determi-
nants can be defined by their capacity to induce a
host immune response. In the context of transplan-
tation, HLA immunogenicity might be considered
at the cellular (T-cell alloreactivity) and/or the
humoral (B-cell alloreactivity leading to the devel-
opment of HLA-specific antibodies) level, although
it is evident that these immune responses are inter-
dependent and intrinsically linked. The complexity
of T-cell allorecognition and the absence of a readily
available and easily interpretable assay to detect
allospecific T cells in transplant patients have, so
far, hampered the successful development of theo-
retical algorithms to predict the potential of donor
HLA to induce T-cell alloreactivity [2]. In contrast,
the detection of alloantibody responses against HLA
expressed on donor tissue has driven the field of
HLA histocompatibility. The differential capacity of
donor HLA to generate alloantibody responses and
the favorable graft outcomes in the presence of
‘permissible’ HLA mismatches have long been rec-
ognized [3,4], driving attempts to create algorithms
that define the potential of donor HLA to induce
humoral alloresponses. HLA immunogenicity in the
context of humoral alloimmunity is the focus of
the present review.
The relationship between amino acid polymor-
phisms on donor HLA with alloantibody responses
and kidney transplant outcomes was recognized
over 2 decades ago and these observations have
formed the basis of subsequent HLA immunogenic-
ity algorithms [5,6]. Most significant in this regard
has been the description of HLAMatchmaker by
Duquesnoy et al. a computer algorithm that aims
to determine the capacity of donor HLA to induce
humoral alloimmunity by evaluating differences in
the number and location of amino acid polymor-
phisms at continuous (triplets) and discontinuous
(eplets) positions between donor and recipient HLA
molecules [7,8]. The fundamental premise of HLA-
Matchmaker is that eplets, small patches of mis-
matched amino acids on or near the molecular
surface of HLA, are potential immunogenic epitopes
that define the specificity of HLA-specific antibod-
ies. To verify this hypothesis, HLAMatchmaker has
been used to analyze alloantibody binding profiles
in patient sera with a view to describing HLA-
specific antibody reactivity based on reactive epletsVolume 23  Number 4  August 2018
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such eplets, termed ‘antibody-verified’ eplets, are
recorded in a publically accessible registry (http://
www.epregistry.com.br/). It is evident, however,
that this approach is not straight-forward [con-
founded by the presence of multiple alloantibodies
in a patient’s serum, variations in single-antigen
bead assay analysis – including in the use of mean
fluorescence intensity (MFI) cutoff values etc.] and
often leads to complex theoretical interpretation,
such as the hypothetical requirement for combina-
tions of multiple eplets or of ‘self’ eplets, to explain
alloantibody reactivity [11]. It is not, therefore, clear
whether B-cell epitopes are adequately defined by
HLAMatchmaker eplets and the feasibility of an
epitope (eplet)-based approach to donor–recipient
matching, and to organ sharing, as has recently been
suggested, remains doubtful [12].
The principal hypothesis underpinning theoret-
ical approaches to predicting the risk of develop-
ment of HLA-specific antibody is that HLA
allorecognition by recipient B-cells is more likely
the more ‘different’ the donor HLA is compared with
recipient HLA molecules. In this regard, HLA immu-
nogenicity algorithms should aim to quantify a
measure of ‘dissimilarity’ between donor and recipi-
ent HLA. The HLAMatchmaker algorithm has been
used successfully in this context as multiple studies
have shown an association between the total num-
ber of eplets present on HLA class I and II mis-
matches (termed ‘eplet load’) and the risk of
development of HLA-specific antibodies [13
&
,14–
16] (recently reviewed in [12]). Many studies in this
field are often confounded by their retrospective
design and the lack of multivariate modeling. Wiebe
et al., however, have recently performed a relatively
large, single-center, prospective study that benefited
from high-resolution HLA typing, information on
immunosuppression levels and patient adherence
and from serial posttransplant antibody monitor-
ing. Their analysis demonstrated that donor HLA-
DR and HLA-DQ eplet load, along with tacrolimus
trough levels, were independent predictors of devel-
opment of donor-specific antibody (DSA) [17
&&
].
The clinical utility of this molecular definition
of donor–recipient HLA compatibility has been
highlighted by studies demonstrating an association
between donor HLA eplet load and the development
of transplant glomerulopathy, acute kidney graft
rejection and graft loss, as well as chronic lung
allograft dysfunction and pediatric heart transplant
loss [18–21]. It is important to emphasize that the
majority of the aforementioned studies on risk of
humoral alloimmunity investigated the overall
immunogenicity score (eplet load) of mismatches
within an HLA locus (the sum of eplets for one or1087-2418 Copyright  2018 The Author(s). Published by Wolters Kluwetwo HLA mismatches within the locus) and the
likelihood of a locus-specific alloantibody response
(to any of the mismatched alloantigens). The immu-
nological basis of this type of analysis might be
inconsistent with the underlying hypothesis in so
far as, in cases in which a high eplet load reflects the
sum of a low eplet and a high eplet HLA mismatch
within the same locus, the alloantibody response
might be directed against the low eplet donor HLA.
Given that a molecular definition of HLA compati-
bility requires discrimination between low vs. high
immunogenicity single HLA mismatches, future
studies should aim to address this potential con-
founder.
An alternative approach to predicting HLA
immunogenicity by assessment of the ‘dissimilar-
ity’ between donor and recipient HLA, based on
information derived from amino acid sequence
analysis, has also been described. The Cambridge
HLA immunogenicity algorithm performs inter-
locus (for HLA class I) and intralocus (for HLA class
II) comparisons between donor and recipient HLA
to enumerate all mismatched amino acid sequence
polymorphisms on donor HLA which are then
scored according to their physicochemical proper-
ties (hydrophobicity and electrostatic charge).
Analysis of alloantibody responses in highly sensi-
tized patients awaiting kidney transplantation,
using this approach, showed that the capacity of
donor HLA to induce a humoral response depends
not only on the number of its polymorphic residues
but also on the physicochemical nature of their side
chains [22,23]. In these studies, consideration of
only surface accessible amino acid polymorphisms
did not improve the power of the model to predict
alloantibody responses. Assessment of the electro-
static charge of amino acid polymorphisms on
donor HLA-A and HLA-B alloantigens has been
shown to correlate independently (accounting for
the number of amino acid mismatches) with risk of
DSA development in both highly sensitized patients
and against HLA class I mismatches expressed on
a failed kidney allograft [13
&
,23]. However, due
to the correlation between the number of amino
acid polymorphisms expressed on a donor HLA and
their overall physicochemical disparity, assessment
of donor–recipient HLA physicochemical differen-
ces at the sequence level has not been shown
to provide an advantage, over simple enumeration
of amino acid mismatches, in assessing the risk




The aforementioned studies demonstrate that
assessment of donor–recipient HLA mismatch at the
amino acid sequence level enables quantification of
the degree of mismatch improving the precisionr Health, Inc. www.co-transplantation.com 479
FIGURE 1. Correlation between amino acid sequence-based human leukocyte antigen mismatch scoring methods;
HLAMatchmaker eplet load vs. number of amino acid mismatches or sequence-based electrostatic mismatch score. This figure
depicts analyses of the immunogenic potential of human leukocyte antigen class II mismatches in a large cohort of kidney
transplant recipients using HLAMatchmaker and the Cambridge human leukocyte antigen immunogenicity algorithm. The
strong correlation between number of eplet mismatches (eplet load), amino acid mismatches and sequence-based electrostatic
mismatch score for human leukocyte antigen mismatches within the human leukocyte antigen-DRb1, human leukocyte antigen-
DRb3/4/5, human leukocyte antigen-DQa1b1 loci is evident. Reproduced with permission [24
&].
Histocompatibilityof immunological risk assessment with DSA devel-
opment as the immune response readout. The
potential benefit of using a particular computa-
tional algorithm to assess HLA immunogenicity
was recently examined in a cohort of 596 renal
transplant patients that were prospectively followed
for DSA development against HLA-DR and HLA-DQ
mismatches, accounting for immunosuppression
therapy and recipient nonadherence [24
&
]. This
study showed that all donor HLA immunogenicity
scoring methods, eplet mismatch load or number
of amino acid mismatches or sequence-based elec-
trostatic mismatch score (EMS), were significant
multivariate correlates of DSA development out-
performing conventional HLA mismatch grade for
this purpose. No advantage was demonstrated
in using one approach over another and each
method provided equivalent assessment of immu-
nological risk associated with donor HLA class II
mismatches. As might be expected, there was strong
correlation between molecular mismatch scores
(R2¼0.85–0.96) highlighting the fact they all reflect
differences in donor–recipient amino acid sequence
(Fig. 1).480 www.co-transplantation.comASSESSMENT OF HUMAN LEUKOCYTE
ANTIGEN IMMUNOGENICITY AT THE
TERTIARY STRUCTURE LEVEL
Even though amino acid sequence-based methods
have been successful in predicting the risk of
humoral alloimmunity after transplantation and
in quantifying donor–recipient HLA incompatibil-
ity, sequence information alone provides limited
insight into the structural aspects of HLA allorecog-
nition by recipient B-cell receptors. Given the
conformational nature of the majority of B-cell
epitopes, a fully structural approach might be
required to capture and characterize their immuno-
genic potential. Epitope–paratope interactions are
largely governed by short-range electrostatic inter-
actions, such as van der Waals forces, hydrogen
bonds and salt-bridges [25], which are important
determinants of the affinity and specificity of anti-
body–antigen binding [26]. It has also been sug-
gested that the process of affinity maturation
involves optimization of electrostatic interactions
in the B-cell receptor–antigen binding site [26–29].
Previous studies have shown that HLA B-cell epito-
pes can be described accurately by their uniqueVolume 23  Number 4  August 2018
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explain serological patterns of HLA-specific anti-
body binding [30–32]. Given that recipient B-cells
do not recognize self HLA molecules, it might be
hypothesized that donor HLA with disparate elec-
trostatic potential profiles compared with recipient
HLA molecules might be recognized more efficiently
by recipient B-cell receptors leading to improved
selection and survival of differentiated B-cells
during the process of affinity maturation in the
germinal center. Indeed, recent insights into the
mechanisms that determine the fate decision of
proliferating, antigen-activated B-cells at the preger-
minal center stage suggested that B-cells with higher
affinity to their antigen presented more HLA-pep-
tide to and made longer lasting contact with cognate
T follicular helper cells at the B-cell–T-cell border in
secondary lymphoid organs, resulting in more T-cell
help and differentiation into germinal center B-cells
[33,34]. These observations have recently led to the
development of a novel HLA immunogenicity algo-
rithm that enables quantitative comparison of sur-
face electrostatic potential properties between
donor and recipient HLA at the tertiary structure
level (EMS-three–dimensional; a description of the
methodology, applied to the study of HLA B-cell
epitopes, is provided in [30]). This approach was
applied to examine humoral alloimmune responses
in healthy females subjected to a standardized injec-
tion of donor lymphocytes from their male partner.
Preliminary results, published in abstract form
[35,36] showed a strong association between the
EMS-three-dimensional of donor HLA and donor-
specific alloantibody development (Mallon et al.
[37], article in submission). The algorithm was also
used to analyze donor–recipient HLA compatibility
in a large cohort of kidney transplant recipients, and
a preliminary report suggested a strong association
between EMS-three-dimensional and risk of graft
failure using a multivariate Cox regression model
of graft survival [38]. This is a developing field of
research and further work is required to determine
the potential of this approach to provide a fully
structural description of HLA immunogenicity
and whether it might enable improved assessment
of donor–recipient histocompatibility compared to
conventional HLA matching and to HLA amino acid
sequence-based algorithms.T-CELL APPROACHES TO PREDICTING
HUMAN LEUKOCYTE ANTIGEN
IMMUNOGENICITY
The above-mentioned approaches to determining
the immunogenicity of HLA have predominantly
focused on the B-cell component of humoral1087-2418 Copyright  2018 The Author(s). Published by Wolters Kluwealloimmunity. Proliferation and differentiation of
antigen-specific naı̈ve B-cells into memory B-cells
and long-lived plasma cells requires T-cell help
through linked recognition of antigenic peptides
presented in the context of B-cell HLA class II mol-
ecules [39]. The implication of this mechanism is
that the capacity of recipient HLA class II molecules
to present donor-HLA-derived peptides is a critical
determinant of the risk of DSA development, and
this was supported by observational studies that
showed an association between the recipient HLA-
DR phenotype and humoral alloresponses to donor
HLA class I alloantigens [40,41]. This concept has
recently been applied into a computational algo-
rithm that enables enumeration of putative CD4þ T-
cell epitopes derived from donor HLA (predicted
indirectly recognizable HLA epitopes or PIRCHE-
II) [42]. PIRCHE implements the NetMHCIIpan pro-
gram which predicts peptide binding affinity into
the groove of an HLA class II molecule based on a
neural network method trained on a set of quanti-
tative peptide binding data [43,44]. For a given
peptide length, the program identifies potential
core nonamer (9-mer) peptides contained within
it and outputs the binding affinity of the highest
scoring nonamer. In the PIRCHE implementation,
predicted nonameric binding cores must be poly-
morphic compared with the recipient’s own HLA
molecules. The algorithm enables processing of
donor HLA classes I and II alloantigens to derive
putative candidate peptide fragments but assess-
ment of peptide binding affinity is currently limited
to recipient HLA-DR molecules. Donor-derived can-
didate peptides with predicted binding of IC50 (half
maximal inhibitory concentration) less than
1000 nmol/l to recipient HLA-DR are summed to
produce the PIRCHE score. The number of PIRCHE
peptides derived from HLA class I mismatches was
shown to correlate in univariate analyses with devel-
opment of DSA after graft nephrectomy and after
pregnancy, although there was a significant overlap
in PIRCHE scores between immunogenic and non-
immunogenic donor HLA [42,45]. In a more recent
study that investigated a large cohort of kidney
transplant patients (n¼2787), the overall PIRCHE
score for the total number of donor–recipient HLA-
A, HLA-B, HLA-C, HLA-DR and HLA-DQB mis-
matches (sum of PIRCHE scores derived from every
HLA mismatch in a given donor–recipient combi-
nation) was an independent predictor of risk of
development of DSA (defined as alloantibody
against any of the mismatched donor HLA; area-
under-the-curve: 0.641), after adjustment for HLA-
Matchmaker eplet mismatching and for conven-
tional HLA mismatching (there was no data on
posttransplant immunosuppression regimens andr Health, Inc. www.co-transplantation.com 481
FIGURE 2. Correlation between predicted indirectly recognizable HLA epitopes and amino acid sequence polymorphism. The
figure depicts analysis of HLA (A, B, C, DR, DQ and DP) mismatches in a local cohort of 182 donor–recipient pairs (HLA typed
at two-field resolution). HLA mismatches were identified (n¼1615) and scored according to the number of possible peptide
epitopes (unique, polymorphic nonameric binding cores) that can be derived from donor HLA (irrespective of predicted binding
affinity to recipient HLA-DR), the number of predicted indirectly recognizable HLA epitopes (predicted indirectly recognizable HLA
epitopes; defined as polymorphic nonameric binding cores with predicted binding to recipient HLA-DR of IC50<1000nmol/l),
and the number of amino acid mismatches (as defined by the Cambridge HLA immunogenicity algorithm). Donor HLA-derived
polymorphic nonameric binding cores were defined as those that differed by at least one amino acid compared with the HLA
sequences of the recipient. The NetMHCIIpan version 3.1 algorithm was implemented locally to calculate the predicted indirectly
recognizable HLA epitopes scores (the predicted indirectly recognizable HLA epitopes algorithm available via https://
www.pirche.org implements a previous version of NetMHCIIpan). For the purposes of this analysis, all HLA mismatches were
grouped together. There was high correlation between scores (Spearman’s Rho), although this correlation varied for mismatches
within individual HLA loci (data not shown). HLA, human leukocyte antigen.
Histocompatibility
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&
]. However, the same
independent effect was not confirmed in a similar
analysis of a subgroup of these patients (n¼1247)
with the most complete pretransplant and post-
transplant antibody monitoring in which the total
number of HLA eplets was the best predictor of risk
of DSA responses. It was notable that after analysis of
locus-specific alloantibodies, the PIRCHE score did
not correlate with risk of development of DSA
against individual HLA-A, HLA-B, HLA-C, HLA-DR
and HLA-DQB alloantigens when two HLA mis-
matches were present in the locus and, therefore,
further studies are needed to determine whether
PIRCHE can be used to predict the immunogenicity
of individual HLA mismatches. When the effect of
this approach on kidney graft outcomes was ana-
lyzed in this study, and more recently in an inde-
pendent patient cohort [47
&
], PIRCHE mismatching
correlated with graft survival, although it is not clear
whether this effect is independent of conventional
HLA matching and/or eplet mismatching (only uni-
variate analysis was performed in the Lachmann
et al. [46
&
] study and a forward stepwise selection
multivariable model – that might not be appropri-
ate in cases of multicollinearity – was used in the
Geneugelijk et al. [47
&
] study). The challenge of
confirming an independent effect of a novel HLA
scoring system on graft survival, over and above that
observed with conventional HLA matching, is better
appreciated considering the significant correlation
between HLA scoring variables (e.g. there was high
correlation between PIRCHE scores and HLAMatch-
maker scores – Spearman’s Rho of 0.75 – and
between PIRCHE scores and conventional HLA mis-
matches in the study by Lachmann et al. [46
&
]). To
illustrate the latter observation, we examined the
relationship between the number of possible pep-
tide epitopes (unique, polymorphic nonameric
binding cores) that can be derived from donor
HLA (irrespective of predicted binding affinity to
recipient HLA-DR), the number of PIRCHE epitopes
(with predicted binding to recipient HLA-DR of IC50
<1000 nmol/l) and the number of amino acid poly-
morphisms present in HLA-A, HLA-B, HLA-C, HLA-
DR, HLA-DQ and HLA-DP mismatches within a local
cohort of 182 donor–recipient pairs. As shown in
Fig. 2, there was high correlation between HLA
scoring systems (although there was variation of
PIRCHE scores for the same number of amino acid
polymorphisms) suggesting that, to an extent, the
current PIRCHE approach reflects donor HLA poly-
morphism at the amino sequence level. Overall,
PIRCHE is an interesting approach for assessing
potential CD4þ T-cell epitopes derived from
donor HLA and how this might impact on risk
of humoral alloimmunity after transplantation.1087-2418 Copyright  2018 The Author(s). Published by Wolters KluweFurther improvements of CD4þ T-cell alloreactivity
prediction algorithms might arise from consider-
ation of peptide presentation by recipient HLA-
DQ and/or HLA-DP and from experimental valida-
tion of predicted epitopes that could inform the
theoretical design of computational algorithms
(e.g. by investigating the predicted peptide binding
affinity cutoff values that best reflect experimental
observations).CONCLUDING REMARKS AND FUTURE
DIRECTIONS
There is currently great need to develop and imple-
ment clinically applicable algorithms that enable
better assessment of donor–recipient HLA incom-
patibility and of the associated immunological risk,
both at a population and at the individual patient
level, to maximize the benefits of transplantation. It
is evident from the aforementioned studies that
significant progress has been made, but there are
a number of challenges to overcome to facilitate a
sea change in the field. Significant in this regard is
the heterogeneity of studies investigating HLA
immunogenicity that limits interpretation and syn-
thesis of available evidence. This heterogeneity
pertains to a number of factors that introduce
uncertainty, including the level of HLA typing
resolution (serological, one-field, two-field), Lumi-
nex single antigen bead output interpretation (e.g.
MFI cutoff values used for antibody detection),
availability of prospective DSA monitoring, adjust-
ment for significant confounders (e.g. immuno-
suppression regimen, patient adherence) and
methodological model used for determining the
association between HLA immunogenicity score
and DSA response (e.g. immunogenicity score of
individual HLA mismatches and DSA response to
the same antigen vs. total immunogenicity score at
an HLA locus level and alloantibody response to any
of the locus mismatches vs. total immunogenicity
score of all donor–recipient HLA mismatches and
alloantibody response to any of these mismatches).
International collaboration and setting up of mul-
ticenter consortia will be required to address these
sources of bias and facilitate the design of large,
appropriately powered, datasets to investigate the
predictive power of HLA immunogenicity algo-
rithms and how they might be applied in the
clinical setting. Future studies should focus on
investigating how HLA immunogenicity algo-
rithms might be applied to improve organ alloca-
tion policies (provided that a clear benefit over
conventional HLA matching at the antigen level
is demonstrated) and model how any changes
might impact equity of access to transplantation.r Health, Inc. www.co-transplantation.com 483
HistocompatibilityIn addition, prospective studies will be needed to
evaluate the potential of HLA immunogenicity
analysis to assess immunological risk and facilitate
clinical decision making at individual patient level
[48]. There is also an impetus on continuing
improvement of currently available algorithms
and/or development of new approaches. This
relates to both B-cell and T-cell HLA immunogenic-
ity algorithms which might be further improved by
better definition of the structure and physicochem-
ical properties of HLA B-cell epitopes (e.g. through
experimental resolution of alloantibody-HLA struc-
tures and computational approaches [49]), more
accurate prediction of T-cell epitopes (including
experimental epitope validation and cross-fertiliza-
tion from relevant fields [50–52]), and from devel-
opment of combined approaches that incorporate
all aspects of alloreactivity.Acknowledgements
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